Acute Disseminated Encephalomyelitis, Encephalomyelitis, Encephalopathy
Conditions
Keywords
ADEM, Pediatric Encephalomyelitis, Demyelinating Disorders
Brief summary
The aim of the present study is to determine outcome predictors in children who were diagnosed as acute disseminated encephalomyelitis (ADEM).
Detailed description
Outcome predictors in children with Acute Disseminated Encephalomyelitis
Interventions
None listed
Sponsors
Assiut University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children aged from 6 months old to 18 years. * Presence of clinical signs of acute encephalopathy with multifocal neurological deficits. * MRI findings suggestive of demyelinating lesions.
Exclusion criteria
* Pediatric patients diagnosed who were as multiple sclerosis. * Pediatric patients with clinical signs and radiological findings suggestive of neuromyelitis optica spectrum disorder. * Pediatric patients with infectious encephalitis. * Pediatric patients with metabolic or genetic neurological disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Patients Achieving Complete Recovery Assessed by the Modified Rankin Scale (mRS) | 6 months | Functional disability and recovery are assessed using the Modified Rankin Scale (mRS), a validated 7-point scale ranging from 0 to 6. A score of 0 indicates no symptoms at all, 5 indicates severe disability (bedridden, requiring constant care), and 6 indicates death. For this study, complete recovery is defined as achieving an mRS score of 0 or 1 (no significant disability). This measure reports the percentage of participants who meet this specific recovery criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Disease Relapse | up to 12 months | This measure evaluates the percentage of participants who experience a new inflammatory demyelinating event. As per the study protocol, a relapse is specifically defined as the onset of a new neurological event occurring more than 3 months after the patient's initial clinical recovery. |
| Incidence of Residual Neurological Deficits | up to 12 months | This measure reports the proportion of participants who exhibit long-term cognitive or motor sequelae following the acute disease phase. The presence or absence of these residual deficits is determined through standard clinical neurological examinations conducted during outpatient follow-up. |
Contacts
CONTACTNorma S Girgis
Outcome results
None listed